

The ORAL Surveillance JAK Inhibitor Controversy

Written by The Life Science Feed Editorial Team · Published 1 June 2026 · Edited by James Carter

KEY TAKEAWAYS

- JAK inhibitors offer comparable or superior efficacy to anti-TNF in RA with oral convenience
- ORAL Surveillance: tofacitinib showed significantly higher MACE and malignancies vs anti-TNF in high-CV-risk patients - but population was specifically selected, limiting generalisability
- Boxed warning applies class-wide; guidelines recommend biologics first in high CV, malignancy, or thrombosis risk patients
- Risk-stratified prescribing: younger patients without risk factors remain candidates for JAKi after csDMARD failure

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Ytterberg SR et al. ORAL Surveillance. N Engl J Med. 2022;386:316-326
2. Dougados M et al. MONARCH. Ann Rheum Dis. 2017;76:1348-1356
3. Smolen JS et al. EULAR RA Management Recommendations. Ann Rheum Dis. 2023
4. Fraenkel L et al. ACR RA Treatment Guidelines. Arthritis Rheumatol. 2021

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com